P-selectin, E-selectin, and CD40L over time in chronic hemodialysis patients

Hemodialysis International

Volumn 16, Issue 1, 2012, Pages 38-46

  Bossola, Maurizio ^a   Rosa, Fausto ^a   Tazza, Luigi ^a   de Curtis, Amalia ^b   Costanzo, Simona ^b   Vulpio, Carlo ^a   Iacoviello, Licia ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cardiovascular disease; CD40L; E selectin; Hemodialysis; P selectin

Indexed keywords

CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; MEASUREMENT; MORTALITY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CD40 LIGAND; E-SELECTIN; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; RENAL DIALYSIS;

EID: 84856405472     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00579.x     Document Type: Article

References (50)

1. United States Renal Data System. 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2006. Available from: (accessed date: June 1, 2010).
2. Registro Italiano Dialisi e Trapianto. Available from: (accessed date: June 1, 2010).
3. Collins AJ, Foley RN, Herzog C, etal. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010; 55(Suppl 1):S1-420, A6-7.
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352:1685-1695.
5. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357:2482-2494.
6. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007; 27:2292-2301.
7. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol. 2009; 103(Suppl):4A-10A.
8. Cerletti C, Evangelista V, de Gaetano G. P-selectin-beta 2-integrin cross-talk: A molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. Thromb Haemost. 1999; 82:787-793.
9. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res. 2009; 123:617-621.
10. Brueckmann M, Bertsch T, Lang S, etal. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med. 2004; 42:1132-1139.
11. Napoleão P, Santos MC, Selas M, Viegas-Crespo AM, Pinheiro T, Ferreira RC. Variations in inflammatory markers in acute myocardial infarction: A longitudinal study. Rev Port Cardiol. 2007; 26:1357-1363.
12. Boaz M, Matas Z, Biro A, etal. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999; 56:1078-1083.
13. Qi BT, Wang P, Li J, Ren HX, Xie M. Levels of soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-2 in plasma of patients with hemorrhagic fever with renal syndrome, and significance of the changes in level. Viral Immunol. 2006; 19:565-569.
14. Sanguigni V, Pignatelli P, Lenti L, etal. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005; 111:412-419.
15. Nasuno A, Matsubara T, Hori T, etal. Levels of soluble E-selectin and ICAM-1 in the coronary circulation of patients with stable coronary artery disease: Association with the severity of coronary atherosclerosis. Jpn Heart J. 2002; 43:93-101.
16. Matsumoto K, Fujishima K, Moriuchi A, Saishoji H, Ueki Y. Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type 2 diabetes mellitus. Metabolism. 2010; 59:320-324.
17. Hulthe J, Wikstrand J, Mattsson-Hulten L, Fagerberg B. Circulating ICAM-1 (intercellular cell-adhesion molecule 1 is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men: The Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond). 2002; 103:123-129.
18. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005; 112:976-983.
19. Blann AD, McCollum CN, Lip GY. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis. 2002; 13:513-518.
20. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol. 1997; 59:115-120.
21. Holmlund A, Hulthe J, Millgard J, Sarabi M, Kahan T, Lind L. Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis. 2002; 165:271-276.
22. Rauchhaus M, Gross M, Schulz S, etal. The E-selectin SER128ARG gene polymorphism and restenosis after successful coronary angioplasty. Int J Cardiol. 2002; 83:249-257.
23. Peter K, Nawroth P, Conradt C, etal. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol. 1997; 17:505-512.
24. Arici M, Kahraman S, Genctoy G, etal. Association of mineral metabolism with an increase in cellular adhesion molecules: Another link to cardiovascular risk in maintenance haemodialysis? Nephrol Dial Transplant. 2006; 21:999-1005.
25. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: Association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant. 2000; 15:1624-1630.
26. de Lemos JA, Zirlik A, Schönbeck U, etal. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: Results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2005; 25:2192-2196.
27. Aukrust P, Muller F, Ueland T, etal. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndrome. Circulation. 1999; 100:614-620.
28. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol. 2005; 96:339-345.
29. Schönbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104:2266-2268.
30. Peng DQ, Zhao SP, Li YF, Li J, Zhou HN. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta. 2002; 319:19-26.
31. Novo S, Basili S, Tantillo R, etal. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke. 2005; 36:673-675.
32. Ferro D, Loffredo L, Polimeni L, etal. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol. 2007; 27:2763-2768.
33. Heeschen C, Dimmeler S, Hamm CW, etal. Soluble CD40 ligand in acute coronary syndrome. N Engl J Med. 2003; 348:1104-1111.
34. Varo N, de Lemos JA, Libby P, etal. Soluble CD40L: Risk prediction after acute coronary syndrome. Circulation. 2003; 108:1049-1052.
35. Lim PS, Wu MY, Chien SW, etal. Elevated circulating levels of soluble CD40 ligand in hemodialysis patients with symptomatic coronary heart disease. Nephrology. 2008; 13:677-683.
36. Heeringa J, Conway DS, van der Kuip DA, etal. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: The Rotterdam Study 1990-1999. J Thromb Haemost. 2006; 4:1944-1949.
37. Eschen O, Christensen JH, Johnsen SP, Dethlefsen C, Schmidt EB. Adhesion molecules and C-reactive protein are associated to adverse events in angina pectoris. Scand Cardiovasc J. 2010; 44:153-160.
38. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003; 33:941-948.
39. Blann AD, McCollum CN. Increased soluble P selectin in peripheral artery disease: A new marker for the progression of disease. Thromb Haemost. 1998; 80:1031-1032.
40. Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin in ischaemic heart disease: A new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis. 1997; 8:383-390.
41. Ridker PM, Buring JE, Rifai N. Soluble P selectin and the risk of future cardiovascular events. Circulation. 2001; 103:491-495.
42. Lip GYH, Blann AD, Edmunds E, Beevers DG. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in hypertension. Blood Coagul Fibrinolysis. 2002; 13:35-42.
43. Hollander JE, Muttreja R, Dalesandro MR, Shofer FS. Risk stratification of emergency department patients with acute coronary syndromes using P selectin. J Am Coll Cardiol. 1999; 34:95-105.
44. Hillis GS, Terregino C, Taggart P, etal. Elevated soluble P selectin levels are associated with an increased risk of adverse events in patients with presumed myocardial ischaemia. Am Heart J. 2002; 143:235-241.
45. Hwang SJ, Ballantyne CM, Sharrett AR, etal. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997; 968:4219-4225.
46. Malatino LS, Stancanelli B, Cataliotti A etal. Circulating E-selectin as a risk marker in patients with end-stage renal disease. J Intern Med. 2007; 262:479-487.
47. Blankenberg S, Rupprecht HJ, Bickel C etal. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001; 104:1336-1342.
48. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med. 2002; 13:185-189.
49. Lajer M, Tarnow I, Michelson AD, etal. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21:525-532.
50. Hocher B, Liefeldt L, Quaschning T, etal. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol. 2007; 18:1323-1330.